{"id":277,"date":"2022-09-30T10:00:00","date_gmt":"2022-09-30T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=277"},"modified":"2025-09-09T09:42:35","modified_gmt":"2025-09-09T09:42:35","slug":"china-fic-drug-global-first-in-class-glucokinase-activator-dorzagliatin-oral-antidiabetic-drug-approved-by-china-nmpa-in-2022","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/277.html","title":{"rendered":"[China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Drug Name: Dorzagliatin<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Drug Modality: Small Molecule<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Drug Target:\u00a0<em>\u00a0<\/em>GKA (Glucokinase Activator\u00a0)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Developed By\uff1aHua Medicine<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Approved Date: 2022-10 by China NMPA<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Indication: Type 2 diabetes<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dosage Form and Strength: Tablets, 75 mg<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Product Code: HMS5552<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of \u201cDorzagliatin\u201d, \u591a\u683c\u5217\u827e\u6c40<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of &#8220;Hua Medicine&#8221;, \u534e\u9886\u533b\u836f\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug Name: Dorzagliatin Drug Modality: Small Molecule Drug Target:\u00a0\u00a0GKA (Glucokinase Activator\u00a0) Developed By\uff1aHua Medicine Approved Date: &hellip; <a title=\"[China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2022\/277.html\"><span class=\"screen-reader-text\">[China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-277","post","type-post","status-publish","format-standard","hentry","category-china-fic-drug"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=277"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/277\/revisions"}],"predecessor-version":[{"id":278,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/277\/revisions\/278"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}